Twitter feed

ICYMI: Rick Pazdur leads a discussion of the development and FDA review process for osimertinib—a treatment for NSCLC—in the current edition of Project Livin’ Label, an educational initiative between @FDAOncology and the AACR. CME credit available:

Abstract Deadline: March 15
Early Registration: March 31
The 16th International Conference on Malignant Lymphoma will be held in virtual format June 18-22, 2021. Submit an abstract and register now:
#16ICML @icmlugano

Deadline: 11:59 PM ET, March 15
AACR Members: Voting is currently open for the following AACR offices:
—Board of Directors (5 seats)
—Nominating Committee (4 seats)
Read the candidates' vision statements and cast your votes today:

#AACRFellows Tony Hunter @salkinstitute, William @Kaelin_Lab, Olufunmilayo Olopade @UCCancerCenter, and Dennis Slamon @dgsomucla will discuss "Cancer Biology and the Changing Therapeutic Landscape" in a plenary at the #AACR21 Annual Meeting, Apr 10-15:

#ASCODailyNews Podcast: @LaurenByersMD of @MDAndersonNews highlights a transformative new framework to classify #SCLC into 4 subtypes based on gene expression, paving the way for #PrecisionMedicine

ASCO Daily News: Accelerating Progress in Small Cell Lung Cancer

Dr. Lauren Byers, associate professor of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center, highlights a ne...


New study in Journal of Clinical Oncology (@ASCO_pubs) led by Joyce Liu, MD, MPH shows new targeted agent achieved impressive response rate in trial with patients with uterine serous carcinoma

#ClinicalResearchers are invited to apply for the one-year, $100,000 AACR Clinical Oncology Research (CORE) Training Fellowships. The program provides selected fellows with a unique training opportunity in drug development. Learn more:

Mechanisms, Impact, and Exploitation of Cancer Chromosomal Instability:
David Pellman, @Samuel_Bakhoum, @SPJacksonGroup, and @KarleneCimprich will address this topic in a Discovery Science Plenary Session at #AACR21. Learn more:

Recent publications

Combination of type I and type II MET tyrosine kinase inhibitors as therapeutic approach to prevent resistance. Mol Cancer Ther.

Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res.

All publications



Target identification and validation image
Target identification and validation
Photo of scientist carefully adding fluid to multiple test tubes
Drug discovery and development
Photo of Belfer Center researcher working at computer
Clinical science and correlatives

Strategic alliances

Graphic showing circular relationship of research, medicine, and industry

Our strategic alliances drive research innovations and lead to improved therapies to benefit cancer patients

Collaborate with us

Our people

Background image is a collage of photos showing Belfer Center members
Our team
Our culture
Background image is a collage of photos showing Belfer Center members

Donor highlight

Robert and Renée Belfer’s transformative cumulative Dana-Farber investment of more than $25 million launched the Robert A. and Renée E. Belfer Center for Applied Cancer Science. Their generosity enabled the Belfer Center to integrate its scientific teams, produce innovative cancer models, partner with industry leaders, and accelerate the development of revolutionary therapies to treat cancer. We are grateful for their vision and incredible support.

Photo of donors, Mr. and Mrs Belfer
Go to Top